The global cancer biomarkers market size is estimated at USD 15.58 billion in 2025 and is forecasted to reach around USD 43.05 billion by 2034, accelerating at a CAGR of 11.99% from 2025 to 2034. The North America cancer biomarkers market size surpassed USD 4.99 billion in 2024 and is expanding at a CAGR of 12.02% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Biomarkers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Biomarkers Market, by Type
8.1.1. Breast Cancer
8.1.1.1. Market Revenue and Forecast
8.1.2. Prostate Cancer
8.1.2.1. Market Revenue and Forecast
8.1.3. Colorectal Cancer
8.1.3.1. Market Revenue and Forecast
8.1.4. Cervical Cancer
8.1.4.1. Market Revenue and Forecast
8.1.5. Liver Cancer
8.1.5.1. Market Revenue and Forecast
8.1.6. Lung Cancer
8.1.6.1. Market Revenue and Forecast
8.1.7. Others
8.1.7.1. Market Revenue and Forecast
9.1. Cancer Biomarkers Market, by Biomolecule Type
9.1.1. Genetic Biomarkers
9.1.1.1. Market Revenue and Forecast
9.1.2. Epigenetic Biomarkers
9.1.2.1. Market Revenue and Forecast
9.1.3. Metabolic Biomarkers
9.1.3.1. Market Revenue and Forecast
9.1.4. Proteomic Biomarkers
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. Cancer Biomarkers Market, by Application Type
10.1.1. Drug Discovery and Development
10.1.1.1. Market Revenue and Forecast
10.1.2. Diagnostics
10.1.2.1. Market Revenue and Forecast
10.1.3. Personalized Medicine
10.1.3.1. Market Revenue and Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Forecast
11.1. Cancer Biomarkers Market, by Profiling Technology Type
11.1.1. Omic Technologies
11.1.1.1. Market Revenue and Forecast
11.1.2. Imaging Technologies
11.1.2.1. Market Revenue and Forecast
11.1.3. Immunoassays
11.1.3.1. Market Revenue and Forecast
11.1.4. Cytogenetics-based Tests
11.1.4.1. Market Revenue and Forecast
12.1. Cancer Biomarkers Market, by End User
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast
12.1.2. Academic and Cancer Research Institutes
12.1.2.1. Market Revenue and Forecast
12.1.3. Ambulatory Surgical Centres
12.1.3.1. Market Revenue and Forecast
12.1.4. Diagnostic Laboratories
12.1.4.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Type
13.1.2. Market Revenue and Forecast, by Biomolecule
13.1.3. Market Revenue and Forecast, by Application
13.1.4. Market Revenue and Forecast, by Profiling Technology
13.1.5. Market Revenue and Forecast, by End User
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type
13.1.6.2. Market Revenue and Forecast, by Biomolecule
13.1.6.3. Market Revenue and Forecast, by Application
13.1.6.4. Market Revenue and Forecast, by Profiling Technology
13.1.7. Market Revenue and Forecast, by End User
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Type
13.1.8.2. Market Revenue and Forecast, by Biomolecule
13.1.8.3. Market Revenue and Forecast, by Application
13.1.8.4. Market Revenue and Forecast, by Profiling Technology
13.1.8.5. Market Revenue and Forecast, by End User
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type
13.2.2. Market Revenue and Forecast, by Biomolecule
13.2.3. Market Revenue and Forecast, by Application
13.2.4. Market Revenue and Forecast, by Profiling Technology
13.2.5. Market Revenue and Forecast, by End User
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type
13.2.6.2. Market Revenue and Forecast, by Biomolecule
13.2.6.3. Market Revenue and Forecast, by Application
13.2.7. Market Revenue and Forecast, by Profiling Technology
13.2.8. Market Revenue and Forecast, by End User
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type
13.2.9.2. Market Revenue and Forecast, by Biomolecule
13.2.9.3. Market Revenue and Forecast, by Application
13.2.10. Market Revenue and Forecast, by Profiling Technology
13.2.11. Market Revenue and Forecast, by End User
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type
13.2.12.2. Market Revenue and Forecast, by Biomolecule
13.2.12.3. Market Revenue and Forecast, by Application
13.2.12.4. Market Revenue and Forecast, by Profiling Technology
13.2.13. Market Revenue and Forecast, by End User
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type
13.2.14.2. Market Revenue and Forecast, by Biomolecule
13.2.14.3. Market Revenue and Forecast, by Application
13.2.14.4. Market Revenue and Forecast, by Profiling Technology
13.2.15. Market Revenue and Forecast, by End User
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type
13.3.2. Market Revenue and Forecast, by Biomolecule
13.3.3. Market Revenue and Forecast, by Application
13.3.4. Market Revenue and Forecast, by Profiling Technology
13.3.5. Market Revenue and Forecast, by End User
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type
13.3.6.2. Market Revenue and Forecast, by Biomolecule
13.3.6.3. Market Revenue and Forecast, by Application
13.3.6.4. Market Revenue and Forecast, by Profiling Technology
13.3.7. Market Revenue and Forecast, by End User
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type
13.3.8.2. Market Revenue and Forecast, by Biomolecule
13.3.8.3. Market Revenue and Forecast, by Application
13.3.8.4. Market Revenue and Forecast, by Profiling Technology
13.3.9. Market Revenue and Forecast, by End User
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type
13.3.10.2. Market Revenue and Forecast, by Biomolecule
13.3.10.3. Market Revenue and Forecast, by Application
13.3.10.4. Market Revenue and Forecast, by Profiling Technology
13.3.10.5. Market Revenue and Forecast, by End User
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type
13.3.11.2. Market Revenue and Forecast, by Biomolecule
13.3.11.3. Market Revenue and Forecast, by Application
13.3.11.4. Market Revenue and Forecast, by Profiling Technology
13.3.11.5. Market Revenue and Forecast, by End User
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type
13.4.2. Market Revenue and Forecast, by Biomolecule
13.4.3. Market Revenue and Forecast, by Application
13.4.4. Market Revenue and Forecast, by Profiling Technology
13.4.5. Market Revenue and Forecast, by End User
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type
13.4.6.2. Market Revenue and Forecast, by Biomolecule
13.4.6.3. Market Revenue and Forecast, by Application
13.4.6.4. Market Revenue and Forecast, by Profiling Technology
13.4.7. Market Revenue and Forecast, by End User
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type
13.4.8.2. Market Revenue and Forecast, by Biomolecule
13.4.8.3. Market Revenue and Forecast, by Application
13.4.8.4. Market Revenue and Forecast, by Profiling Technology
13.4.9. Market Revenue and Forecast, by End User
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type
13.4.10.2. Market Revenue and Forecast, by Biomolecule
13.4.10.3. Market Revenue and Forecast, by Application
13.4.10.4. Market Revenue and Forecast, by Profiling Technology
13.4.10.5. Market Revenue and Forecast, by End User
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type
13.4.11.2. Market Revenue and Forecast, by Biomolecule
13.4.11.3. Market Revenue and Forecast, by Application
13.4.11.4. Market Revenue and Forecast, by Profiling Technology
13.4.11.5. Market Revenue and Forecast, by End User
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type
13.5.2. Market Revenue and Forecast, by Biomolecule
13.5.3. Market Revenue and Forecast, by Application
13.5.4. Market Revenue and Forecast, by Profiling Technology
13.5.5. Market Revenue and Forecast, by End User
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type
13.5.6.2. Market Revenue and Forecast, by Biomolecule
13.5.6.3. Market Revenue and Forecast, by Application
13.5.6.4. Market Revenue and Forecast, by Profiling Technology
13.5.7. Market Revenue and Forecast, by End User
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type
13.5.8.2. Market Revenue and Forecast, by Biomolecule
13.5.8.3. Market Revenue and Forecast, by Application
13.5.8.4. Market Revenue and Forecast, by Profiling Technology
13.5.8.5. Market Revenue and Forecast, by End User
14.1. F. Hoffmann-La Roche Ltd.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Thermo Fisher Scientific Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. QIAGEN N.V.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Illumina Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Bio-Rad Laboratories Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Abbott Laboratories
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Exact Sciences
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Meso Scale Diagnostics LLC
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Seegene Technologies Inc.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Siemens Healthineers
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample